+39.0965.624747

CYP2C9*2

CYP2C9*2 Screening test for: Metabolism of Warfarin CYP2C9, one of the members of the family of cytochrome P-450, is responsible for the metabolism of approximately 16% of the drugs currently on the market. It is important for the metabolism of many drugs with a narrow therapeutic range, such as phenytoin (antiepileptic) or anticoagulants Warfarin and Sintrom, and blockers (angiotensin II), non-steroidal anti-inflammatory drugs, some antidepressants and many other drugs. There are several allelic variants of CYP2C9, the most common are the CYP2C9 * 2 (C430T) and CYP2C9 * 3 (A1075C), with an allele frequency in the Caucasian population respectively of 8-18% and 4-10%.

Several studies of patients treated with warfarin showed that individuals with alleles CYP2C9 * 2 and CYP2C9 * 3 metabolize drugs more slowly (low-metabolizers) and therefore require a lower dose of the drug. These alleles were strongly associated with an increased sensitivity to warfarin and risk of bleeding during treatment anticoagulante. There are genotype-phenotype correlations for a better management of the patient: - subjects with genotype CYP2C9 *1/*1 (frequency of 70% in the Caucasian population) are considered normal metabolizers; - individuals CYP2C9 *1/*2 (frequency of 16% in Caucasian populations), and *1/*3 (frequency of 10% in the Caucasian population) are considered poor metabolizers; - finally, there is a class of very poor metabolizer genotype grouping subjects at *2/*2 (frequency of 1%), *2/*3 (frequency 1%), *3/*3 (frequency of 0.3%). The kit is available in sizes from 24, 48 or 72 reactions.

Download and view PDF

bia2Real Gene S.r.l. is a young biotech company that comes from a strong experience of distribution of diagnostic products for the laboratory... Read More

NOTE! This site uses cookies and similar technologies.

If you not change browser settings, you agree to it. Learn more

I understand

Contact

map+39.0965.624747

fax  +39.0965.624747

mail2icon info@realgene.it